The healthcare diagnostics company reports a 15% increase in revenues for the first half of 2025, but also mentions ongoing regulatory and commercial discussions that suggest potential short-term challenges.
The genetics company focused on cardiovascular disease prevention provides an update on its FDA De Novo submission, indicating progress but remaining uncertainty.
The genetic testing firm reported a 25% revenue increase but continues to operate at a loss. Despite market expansions and regulatory progress, financial challenges persist amid a competitive landscape and economic uncertainties.
The healthcare company announces the release of its audited final results and upcoming analyst and investor briefings.
The genetics company provides an update on its FDA submission, indicating ongoing discussions to address outstanding elements identified by the regulator.
The genetics company has granted share options to its directors and employees as part of an incentive scheme.
The diagnostics company announces a decrease in shareholding by a major investor, but the news appears to have no material impact on the business.
The diagnostics company has announced a change in major shareholding, with no further details provided.
The diagnostics company announces a change in major shareholding, with Dowgate Group Limited acquiring a 7.04% stake.
The genetics company has raised £4.1 million through a discounted Retail Offer, suggesting low investor appetite and potential underlying challenges.